Key facts
- This page summarizes Sandip I. Patel's Form 4 filing for Akari Therapeutics Plc (AKTX).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 29 Apr 2025, 17:00.
Sandip I. Patel - 25 Apr 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)
- Reporting relationship
- Director
- Issuer ticker
- AKTX
- Reported as of
- 25 Apr 2025
- Net transaction value
- +$149,997
- SEC form
- 4
- Accepted by SEC
- 29 Apr 2025, 17:00:12 UTC
- Prior SEC filing
- 24 Mar 2025
- Next SEC filing
- 18 Dec 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Torsten Hombeck, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sandip I. Patel filed Form 4 for Akari Therapeutics Plc (AKTX) on 29 Apr 2025.
Change
- Previous filing in this sequence was filed on 24 Mar 2025.
- Current net transaction value: +$149,997.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKTX
transaction
American Depositary Shares representing Ordinary Shares
Award
- Transaction value
- $49,999
- Shares
- +44,642
- Change %
- +9.9%
- Price
- $1.12
- Shares after
- 496,499
- Date
- 06 Mar 2025
- Ownership
- Direct
- Footnotes
- F1, F2
AKTX
holding
American Depositary Shares representing Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,250
- Date
- 25 Apr 2025
- Ownership
- TT Insurance Investment LLC
- Footnotes
- F1
AKTX
holding
American Depositary Shares representing Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 13,901
- Date
- 25 Apr 2025
- Ownership
- Innovative Lifesci Investments LLC
- Footnotes
- F1
AKTX
holding
American Depositary Shares representing Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 19,880
- Date
- 25 Apr 2025
- Ownership
- Quest Bio LLC
- Footnotes
- F1
AKTX
holding
American Depositary Shares representing Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 20,219
- Date
- 25 Apr 2025
- Ownership
- Davis Island Ventures LLC
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AKTX
transaction
Derivative
Series A Warrants (Right to Buy)
Award
- Transaction value
- $49,999
- Shares
- +44,642
- Change %
- Price
- $1.12
- Shares after
- 44,642
- Date
- 06 Mar 2025
- Ownership
- Direct
- Underlying class
- American Depositary Shares representing Ordinary Shares
- Underlying amount
- 44,642
- Exercise price
- $0.8700
- Footnotes
- F1, F2
AKTX
transaction
Derivative
Series B Warrants (Right to Buy)
Award
- Transaction value
- $49,999
- Shares
- +44,642
- Change %
- Price
- $1.12
- Shares after
- 44,642
- Date
- 06 Mar 2025
- Ownership
- Direct
- Underlying class
- American Depositary Shares representing Ordinary Shares
- Underlying amount
- 44,642
- Exercise price
- $0.8700
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.
Footnote F2
On April 25, 2025, the Reporting Person acquired 44,642 ADS and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.